Immunovant's total assets for Q3 2025 were $420.93M, a decrease of -18.38% from the previous quarter. IMVT total liabilities were $68.31M for the fiscal quarter, a 2.49% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.